Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab

BACKGROUND: We evaluated shedding of epidermal growth factor type II receptor (Her2/neu) extracellular domain (ECD) in primary uterine serous carcinoma (USC) cell lines and in the serum of USC patients and its biological effects in experiments of trastuzumab-induced cytotoxicity in vitro. METHODS: H...

Descripción completa

Detalles Bibliográficos
Autores principales: Todeschini, P, Cocco, E, Bellone, S, Varughese, J, Lin, K, Carrara, L, Guzzo, F, Buza, N, Hui, P, Silasi, D-A, Ratner, E, Azodi, M, Schwartz, P E, Rutherford, T J, Pecorelli, S, Santin, A D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208497/
https://www.ncbi.nlm.nih.gov/pubmed/21915118
http://dx.doi.org/10.1038/bjc.2011.369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208497/
https://www.ncbi.nlm.nih.gov/pubmed/21915118
http://dx.doi.org/10.1038/bjc.2011.369

Ejemplares similares